Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company posted a loss of $1.17. Insmed generated total revenues of $75.5 million during the quarter, which were up 16% year over year. The reported sales missed the Zacks Consensus Estimate of $78.9 million. Quarter in Detail In the reported quarter, total revenues were generated entirely from product revenues of Insmed's only marketed drug, Arikayce, which is approved for treating refractory mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. The rise in Arikayce sales was driven by continued growth in demand across all marketed regions. Sales of the drug were up 15% to $56.3 million in the United States, while sales in Japan rose 13% to $14.9 million. Sales in Europe and the rest of the world surged 42% to $4.3 million. In the reported quarter, selling, general and administrative (SG&A) expenses rose 17% year over year to $93.1 million, driven by increases in compensation and benefit-relate
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International ConfeAcquire Media Monitor
- Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International ConfePR Newswire
- Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $48.00 price target on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $40.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.MarketBeat
INSM
Earnings
- 5/9/24 - Beat
INSM
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/15/24 - Form 4
- INSM's page on the SEC website